UCL has announced a new collaboration with Cerveau Technologies, which will enable UCL to manufacture and distribute the imaging agent called [18F]MK-6240.
Use of the imaging agent will improve understanding of neurodegenerative diseases, and it is hoped that this will ultimately lead to better treatments.
The imaging agent will be used by UCL in clinical studies to assess the status and progression of neurofibrillary tangles (NFTs) in the brain. These NFTs are a hallmark of several neurodegenerative diseases, including Alzheimer’s Disease. UCL is the first site able to distribute [18F]MK-6240 which has been produced in line with best practice in the UK.
Professor Erik Arstad, the Director of the UCL Centre for Radiopharmaceutical Chemistry, said “The team at the UCL Centre for Radiopharmaceutical Chemistry is delighted to provide [18F]MK-6240 to our clinical collaborators at the UCL Dementia Research Centre and the wider biomedical research community in the UK. As the best-in-class imaging biomarker for neurofibrillary tangles (NFTs) in the brain, [18F]MK-6240 will facilitate UK led research into the understanding and treatment of Alzheimer’s Disease.
